Arris' APC-366 to enter Phase IIb asthma trials in 1997 with non-aerosol formulation.
ARRIS' APC-366 TO ENTER PHASE IIB ASTHMA TRIALS IN 1997 IN NON-AEROSOL FORMULATION, the company said April 30 during a teleconference. South San Francisco-based Arris will develop a dry powdered inhaler or metered-dose inhaler formulation for APC-366. "We currently believe that for marketing purposes we need to move forward with either a metered-dose inhaler or a dry-powdered inhaler, with our clear preference at this point to look most closely at a dry-powdered inhaler format for purposes of a Phase IIb study," Arris CEO John Walker said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth